The role of selegiline in the treatment of negative symptoms associated with schizophrenia.
OBJECTIVE
To evaluate the role of selegiline in the treatment of negative symptoms associated with schizophrenia.


METHODS
MEDLINE (1966-January 2007) and PsychINFO (1967-January 2007) were searched, using the terms schizophrenia, negative symptoms, and selegiline. A bibliographic search was conducted, as well.


METHODS
All English-language articles identified from the search were evaluated. All primary literature was included in the review.


RESULTS
Based on its dopamine-enhancing property, selegiline has been studied as augmentation to antipsychotic therapy for the treatment of negative symptoms associated with schizophrenia. The efficacy of low-dose oral selegiline for the treatment of negative symptoms has been evaluated in 1 case report, 2 open-label trials, and 2 controlled trials. The case report and both open-label trials report improvement of negative symptoms associated with low-dose oral selegiline. In 1 of the controlled trials, selegiline showed no difference in effect from that of placebo. These data are limited by small sample sizes. The largest controlled trial demonstrated a statistically significant difference between selegiline and placebo; however, the clinical significance is questionable, given that patients treated with selegiline were still experiencing marked negative symptoms at study completion. No comparative studies evaluating low-dose oral selegiline versus other augmentative treatment options for negative symptoms associated with schizophrenia exist at this time.


CONCLUSIONS
Given the limitations of current literature, low-dose oral selegiline cannot be recommended for treatment of negative symptoms associated with schizophrenia. Additional controlled trials are needed to better delineate whether there is a role for selegiline in decreasing the burden of negative symptoms associated with schizophrenia.
Fohey
Krista D
KD
School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, USA.
Hieber
Robin
R
Nelson
Leigh Anne
LA
D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*
D015259:Dopamine Agents; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline